PCDHGA11

Across TCGA pan-cancer cohorts, PCDHGA11 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PCDHGA11 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher PCDHGA11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PCDHGA11 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

CESC, LUAD, and UCEC are the cancer types where PCDHGA11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.095	0.875	<.001	42	view →
LUAD	DFS	Median	All	0.251	0.775	<.001	26	view →
UCEC	OS	Median	IV	0.259	0.770	<.001	12	view →
BLCA	OS	Median	IV	0.130	0.599	.002	12	view →
READ	OS	Median	All	0.665	0.905	.041	6	view →
LIHC	DFS	Median	All	0.096	0.526	.023	3	view →
SKCM	DFS	Median	III,IV	0.794	0.574	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PCDHGA11–CESC (OS)

Open the CESC breakdown →